The North America Antimicrobial Susceptibility Testing (AST) Market is poised for strong growth due to increasing demand for rapid diagnostic solutions, technological advancements, and rising cases of antimicrobial resistance. The market size was valued at USD 1,155 Million in 2025 and is expected to reach USD 2,540 Million by 2035, expanding at a CAGR of 7.4% from 2024 to 2035.
The economic impact of tariffs on "North America Antimicrobial Susceptibility Testing Market".
Market Growth Drivers
Increasing Prevalence of Antimicrobial Resistance: The alarming rise in antibiotic-resistant infections across North America is fueling the demand for advanced AST solutions. According to the CDC, over 2.8 million antibiotic-resistant infections occur each year in the U.S. alone. This scenario necessitates precise and rapid susceptibility testing, compelling laboratories and healthcare facilities to adopt innovative platforms. Companies like Thermo Fisher Scientific are expanding their AST portfolios to cater to changing pathogen profiles and resistance mechanisms.
Technological Advancements in Rapid Testing Methods: The adoption of automated and high-throughput AST systems has significantly bolstered the market. BioMérieux, for example, continues to innovate with its VITEK systems, offering faster, more reliable results. Hospitals and diagnostic labs benefit from quicker turnaround times, enabling timely and targeted patient treatment, ultimately reducing hospital stays and healthcare costs.
Market Trends
Shift Toward Automated and Digital AST Platforms: The market is witnessing a shift toward fully automated and integrated digital testing solutions. Companies such as BD (Becton, Dickinson and Company) have launched platforms like BD Phoenix, which combine automation with artificial intelligence for improved accuracy. Digital data management and seamless connectivity with Laboratory Information Systems (LIS) are minimizing human error and providing robust, actionable results.
Growth of Point-of-Care AST Devices: There is a growing focus on the development of portable AST devices for rapid, bedside infection diagnosis. Accelerate Diagnostics is at the forefront with its Accelerate Pheno System, which can deliver susceptibility results within hours, rather than days. This trend supports antimicrobial stewardship programs and enhances patient outcomes by enabling timely and targeted therapy in both hospital and outpatient settings.
Market Opportunity
Expansion of Companion Diagnostics: The emergence of personalized medicine in infectious diseases presents a significant opportunity for AST developers. Leading firms like Thermo Fisher Scientific are exploring new companion diagnostics approaches to identify the most effective antibiotics for individual patients.
Rising Government and Private Sector Investments: Increased funding and public-private partnerships are creating avenues for market expansion. Initiatives from organizations like CARB-X and AMR Action Fund are supporting R&D in novel AST technologies and rapid diagnostic tools.
North America Antimicrobial Susceptibility Testing Market Revenue (USD Million), 2020-2035
The chart illustrates the progressive growth of the North America AST market from 2020 to 2035. Starting at USD 800 Million in 2020, the market shows a consistent upward trend due to healthcare digitization, increased adoption in clinical laboratories, and expansion into personalized medicine. By 2025, revenues reach USD 1,155 Million, and the trajectory indicates accelerated growth, surpassing USD 2,540 Million by 2035. Key contributing factors include rapid diagnostic advancements, rising AMR cases, and supportive regulatory reforms. The robust CAGR of 7.4% over this period reflects strong industry momentum and evolving healthcare infrastructure in North America.
North America Antimicrobial Susceptibility Testing Market Share by Region (%), 2025
The pie chart for 2025 reveals that the United States holds the dominant market share at 82%, attributable to its advanced healthcare infrastructure, robust clinical laboratory network, and high R&D investments. Canada follows with 11%, supported by growing healthcare digitization and national antimicrobial resistance strategies. Mexico accounts for 4% as it invests in improved diagnostic access, while the Caribbean and Central American regions share 2% and 1% respectively, reflecting emerging healthcare initiatives. The distribution underscores the United States' leadership but also signals potential for stronger growth in neighboring markets as healthcare awareness rises across North America.
Recent Developments in the North America AST Market
In April 2024, Thermo Fisher Scientific expanded its Sensititre product line with the launch of new, FDA-cleared antimicrobial susceptibility plates designed to address emerging resistance mechanisms. These panels enable more comprehensive detection of multi-drug resistant pathogens and facilitate faster clinical decision-making.
In March 2024, BioMérieux announced a strategic partnership with Microsoft to leverage AI and cloud computing for enhanced data analytics within AST workflows. The collaboration aims to improve real-time surveillance and reporting of resistance patterns across networks of healthcare institutions in North America.
In January 2024, BD (Becton, Dickinson and Company) received Health Canada approval for its BD Phoenix M50 automated microbiology system, enabling wider access to high-throughput AST testing across Canadian hospitals. This move is expected to improve diagnostic turnaround time and support antimicrobial stewardship throughout the region.
Press Releases